,8 To investigate whether such alterations might underlie the observed sensitivity to HDAC inhibition, we analyzed genomic data on the patient-derived UPS cell lines 8 and integrated this with analysis of publicly available and in-house datasets from solid UPS and LMS tumors, including data from the Pan-Cancer Analysis of Whole Genomes (PCAWG) project and Genomics England (GEL) (Supplementary Figure S6).8 The gene discussed is HDAC9; the disease is undifferentiated pleomorphic sarcoma.